FDA-BCAN Workshop: Endpoints for the Development of Neoadjuvant Systemic Therapy Regimens for Muscle-Invasive Bladder Cancer (MIBC)


This workshop brings together stakeholders in the care of patients with muscle-invasive bladder cancer including clinicians, regulatory scientists, biostatisticians, patients, advocates, and industry representatives. Its goals are to define the current state of knowledge regarding endpoints to accelerate the development of systemic therapy regimens in the neoadjuvant setting, identify knowledge gaps, plan strategies for evidence development and generate regulatory guidance to inform ongoing/future clinical trials.

Location: Capital Hilton, Washington, DC, United States

2019 Program

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.